OncoMatch/Clinical Trials/NCT07480954
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Is NCT07480954 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Dual-target CAR-NK cell product and Lymphodepleting chemotherapy for epithelial ovarian cancer.
Treatment: Dual-target CAR-NK cell product · Lymphodepleting chemotherapy — This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. At screening, each participant's tumor is assessed for expression of Mesothelin (MSLN), Folate Receptor alpha (FRalpha/FOLR1), and MUC16 (CA 125). Participants are assigned to the dual-target CAR-NK product that best matches their tumor antigen profile to reduce the risk of antigen escape.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Required: MSLN overexpression above protocol-defined threshold (protocol-defined threshold)
Tumor expresses at least two of the following targets above protocol-defined threshold: MSLN, FRalpha (FOLR1), MUC16 (CA 125)
Required: FOLR1 overexpression above protocol-defined threshold (protocol-defined threshold)
Tumor expresses at least two of the following targets above protocol-defined threshold: MSLN, FRalpha (FOLR1), MUC16 (CA 125)
Required: MUC16 overexpression above protocol-defined threshold (protocol-defined threshold)
Tumor expresses at least two of the following targets above protocol-defined threshold: MSLN, FRalpha (FOLR1), MUC16 (CA 125)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
Cannot have received: gene-modified cellular therapy (car-t, car-nk)
Exception: within 6 months (or any prior therapy directed to the same target, per protocol)
Lab requirements
Blood counts
anc >= 1.0 x 10^9/l; platelets >= 75 x 10^9/l; hemoglobin >= 8 g/dl
Kidney function
creatinine clearance >= 50 ml/min
Liver function
ast/alt <= 3 x uln (<= 5 x uln with liver metastases); total bilirubin <= 1.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07480954 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene-modified cellular therapy disqualifies patients from enrollment.
Does this trial require MSLN?
Yes, MSLN overexpression above protocol-defined threshold is a required biomarker for enrollment.
Does this trial require FOLR1?
Yes, FOLR1 overexpression above protocol-defined threshold is a required biomarker for enrollment.
Does this trial require MUC16?
Yes, MUC16 overexpression above protocol-defined threshold is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify